$484 Million is the total value of Broadfin Capital, LLC's 43 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $41,162,000 | -21.8% | 4,328,303 | -27.3% | 8.50% | +22.7% |
| NVRO | Sell | NEVRO CORP | $38,920,000 | +34.4% | 622,615 | -16.4% | 8.04% | +111.1% |
| CPRX | Sell | CATALYST PHARMACEUTICALS INC | $29,871,000 | +148.2% | 5,856,998 | -6.6% | 6.17% | +289.9% |
| ZGNX | Sell | ZOGENIX INC | $20,447,000 | +4.6% | 371,698 | -30.7% | 4.22% | +64.3% |
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $17,561,000 | -21.3% | 2,469,894 | -5.5% | 3.63% | +23.5% |
| SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $13,904,000 | +10.0% | 2,792,049 | -1.1% | 2.87% | +72.7% |
| REPH | Sell | RECRO PHARMA INC | $11,193,000 | -23.0% | 1,909,995 | -6.7% | 2.31% | +20.9% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $10,856,000 | +28.0% | 148,100 | -26.0% | 2.24% | +100.9% |
| QTNT | Sell | QUOTIENT LTD | $9,899,000 | -4.7% | 1,098,656 | -35.3% | 2.04% | +49.6% |
| INCY | Sell | INCYTE CORP | $8,601,000 | -26.2% | 100,000 | -45.4% | 1.78% | +15.9% |
| NSTG | Sell | NANOSTRING TECHNOLOGIES INC | $8,512,000 | -20.3% | 355,714 | -50.6% | 1.76% | +25.1% |
| XENT | Sell | INTERSECT ENT INC | $8,472,000 | +4.4% | 263,500 | -8.5% | 1.75% | +63.9% |
| SRRA | Sell | SIERRA ONCOLOGY INC | $8,259,000 | +28.2% | 4,829,832 | -1.0% | 1.70% | +101.3% |
| DXCM | Sell | DEXCOM INC | $8,039,000 | -62.7% | 67,500 | -62.5% | 1.66% | -41.4% |
| ATRS | Sell | ANTARES PHARMA INC | $8,011,000 | -14.5% | 2,643,947 | -23.2% | 1.65% | +34.3% |
| IART | Sell | INTEGRA LIFESCIENCES HLDGS C | $7,888,000 | -11.0% | 141,572 | -28.0% | 1.63% | +39.7% |
| OPTN | Sell | OPTINOSE INC | $6,032,000 | +36.9% | 585,600 | -17.6% | 1.24% | +115.0% |
| ADMA | Sell | ADMA BIOLOGICS INC | $5,606,000 | -44.5% | 1,479,243 | -65.0% | 1.16% | -12.8% |
| LIVN | Sell | LIVANOVA PLC | $4,668,000 | +0.1% | 48,000 | -5.9% | 0.96% | +57.3% |
| NEOS | Sell | NEOS THERAPEUTICS INC | $4,207,000 | -2.6% | 1,611,999 | -38.4% | 0.87% | +53.0% |
| TLGT | Sell | TELIGENT INC NEW | $2,310,000 | -40.3% | 1,990,983 | -29.5% | 0.48% | -6.3% |
| ATEC | Sell | ALPHATEC HOLDINGS INC | $1,174,000 | +14.0% | 442,966 | -1.5% | 0.24% | +79.3% |
| OSMT | Sell | OSMOTICA PHARMACEUTICALS PLC | $1,108,000 | -72.9% | 307,854 | -41.8% | 0.23% | -57.5% |
| NVLNF | Sell | NOVELION THERAPEUTICS INC | $897,000 | -13.2% | 729,301 | -40.7% | 0.18% | +36.0% |
| IDRA | Exit | IDERA PHARMACEUTICALS INC | $0 | – | -486,604 | -100.0% | -0.18% | – |
| KALA | Exit | KALA PHARMACEUTICALS INC | $0 | – | -339,119 | -100.0% | -0.22% | – |
| DOVA | Exit | DOVA PHARMACEUTICALS INC | $0 | – | -351,800 | -100.0% | -0.35% | – |
| KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -143,129 | -100.0% | -0.37% | – |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -89,100 | -100.0% | -0.44% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -58,700 | -100.0% | -0.75% | – |
| NVRO | Exit | NEVRO CORPcall | $0 | – | -300,000 | -100.0% | -1.53% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INcall | $0 | – | -350,000 | -100.0% | -1.89% | – |
| TSRO | Exit | TESARO INCcall | $0 | – | -325,000 | -100.0% | -3.17% | – |
| TSRO | Exit | TESARO INC | $0 | – | -442,219 | -100.0% | -4.32% | – |
| XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -700,000 | -100.0% | -6.60% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -700,000 | -100.0% | -23.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.